With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.
In timely and incisive analysis, our experts parse the latest development news and devise practical solutions to new and emerging challenges. Our events convene the top thinkers and doers in global development.
On 12 January, in Tanzania, Gordon Brown told reporters that the UK would be seeking support for an advance purchase scheme for an AIDS vaccine. According to The Daily Telegraph:
"Mr. Brown said the Government would work with other countries to investigate the creation of an advance purchase scheme to encourage drug firms to invest more in HIV/AIDS research.
"If donors committed to buying the first 300 million vaccine courses at $20 per course of vaccinations, that would translate into a $6 billion guarantee - large enough to induce much stronger interest from both large and small pharmaceutical firms," Mr. Brown said."
Last week, Gavi, the Vaccine Alliance, completed a $7.5 billion replenishment to fund its work on immunization in the world’s poorest countries between now and 2020. Gavi’s next step is to ensure that the money is used as effectively as possible to save lives and improve health.
The majority of the world’s sick live in middle-income countries (MIC) – mainly Pakistan, India, Nigeria, China and Indonesia (or PINCI), according to new data from the Institute for Health Metrics and Evaluation (IHME) at the University of Washington. Sound familiar? Andy Sumner, Denizhan Duran, and I came to the same conclusion in a 2011 paper, but we used 2004 disease burden data, which didn’t provide an up-to-date view of reality. So I was pleased to see that our findings still hold based on IHME’s 2010 Global Burden of Disease (GBD) estimates.